2 Ablative RadioTherapy Treatments for Prostate Cancer

NCT ID: NCT04654338

Last Updated: 2023-06-27

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-29
• Study Completion Date: 2028-07-29

Brief Summary

Favorable-risk prostate cancer represent a large proportion of patients diagnosed with prostate cancer and image guided radiation therapy (IGRT) is commonly used to treat these patients using protracted courses of up to 39 treatments over 8 weeks. Stereotactic ablative body radiotherapy (SABR) protocols hold the promise of more convenience, less side effects, less cost and improved system capacity without sacrificing excellent cancer control rates. By the same token, prostate high-dose rate (HDR) brachytherapy boost has been shown to be superior to standard external beam radiation. While two HDR fractions appear to optimize patient convenience and outcomes while minimizing costs, we wanted to determine the tolerability of combining one MR-guided HDR treatment with one SABR treatment to further reduce HDR resource use while maintaining favourable treatment outcomes.

Detailed Description

Pre-Treatment:

Planning CT and mpMRI imaging for SABR TRUS with biopsy and insertion of Gold Seed Fiducial Markers Biobanking of urine, blood and biopsy tissue (as per REB#079-2006 Odette Cancer Centre (OCC) biobanking protocol)

Stereotactic Ablative Body Radiation (SABR):

13.5Gy x 1 to whole prostate + 1cm seminal vesicles 2 weeks post-planning, treatment will be delivered as per standard treatment protocols on SABR-compatible linear accelerator with a six-degree of freedom couch. Cone-beam CT imaging will be performed using the implanted fiducials to set up each treatment. All dosimetric parameters will be recorded.

Inter-treatment (approx 1 week post-SABR):

Planning mpMRI and TRUS imaging for HDR Biobanking of urine and blood (as per REB#079-2006 OCC biobanking protocol)

HDR brachytherapy:

13.5 Gy x 1 to the prostate, <20 Gy to DIL Approx 2-3 weeks post-SABR, the HDR dose prescription of 13.5 Gy to the whole gland and <20 Gy to MRI visible lesion will be delivered in one fraction, assuming that dose constraints to critical organs can be met. All dosimetric parameters will be recorded

Patient Assessments / Follow-up Time zero will be the date of SABR treatment. Baseline rectal, urinary and sexual function will be recorded prior to treatment. Acute toxicities will be assessed at 6, 12 and 24 weeks and late toxicities will be assessed at month 9, 24 and every 6 months until year 5 using the Common Terminology Criteria Adverse Events, V 4.0. Bloodwork (PSA and testosterone) and International Prostate Symptom Score (IPSS) evaluations will be performed at baseline week 6, month 3, 6, 9 and 24, and every 6 months until year 5. QOL using the Expanded Prostate Cancer Index Composite (EPIC), EQ-5D and PORPUS questionnaires will be obtained at baseline, month 3, 6, 9 and 24 and every 6 months until year 5. Post-treatment biobanking will be done at 13 and 52 weeks (as per REB#079-2006 OCC biobanking protocol)

Conditions

Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intervention Arm

Group Type: EXPERIMENTAL

SABR + HDR

Intervention Type: RADIATION

One SABR treatment + one HDR brachytherapy treatment

Interventions

SABR + HDR

One SABR treatment + one HDR brachytherapy treatment

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed diagnosis of adenocarcinoma of the prostate
• Favorable risk disease defined as either:

• Low risk disease: T1-T2c, grade group 1, PSA < 10 ng/ml or
• Favorable intermediate risk disease: One of T2c, grade group 2, or PSA 10-20 ng/ml. Patients cannot have percent core positivity > 50%
• Prostate volume < 60 cc as determined by US, CT or MRI
• Ability to undergo MR imaging
• Provide written informed consent

Exclusion Criteria

• Documented nodal or distant metastases
• Previous pelvic radiotherapy
• Previous transurethral resection of prostate, previous prostatectomy or HIFU
• Use of androgen deprivation therapy. Use of 5-alpha-reductase inhibitors permitted
• Poor baseline urinary function defined as International Prostate Symptom Score (IPSS) >15
• Contra-indication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease
• Significant medical co-morbidity rendering patient unsuitable for general anaesthesia

• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Sunnybrook Health Sciences Centre

OTHER

Sponsor Role: lead

Responsible Party

Andrew Loblaw

GU Radiation Oncology Site Group Lead

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Andrew Loblaw, MD

Role: PRINCIPAL_INVESTIGATOR

Sunnybrook Health Sciences Centre

Locations

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Merrylee McGuffin, MSc

Role: CONTACT

Merrylee.Mcguffin@sunnybrook.ca

416-480-6100 ext. 85454

Facility Contacts

Andrew Loblaw, MD, FRCPC

Role: primary

Andrew.Loblaw@sunnybrook.ca

416-480-4806

Merrylee McGuffin, MSc, MRT(T)

Role: backup

Merrylee.Mcguffin@sunnybrook.ca

416-480-6100 ext. 85454

Other Identifiers

3592

Identifier Type: -

Identifier Source: org_study_id